article
17 March 2016 | By Amy Dawson (University of Hull), John Greenman (University of Hull), Ruth Bower (University of Hull), Victoria Green (University of Hull)
Microfluidic technology has great potential for complementing and, in some instances, replacing the use of animal models in the testing of medicines and in developing personalised treatments for cancer patients.